57,096 Shares in Zimmer Biomet Holdings, Inc. $ZBH Bought by Polar Asset Management Partners Inc.

Key Points

• Polar Asset Management Partners Inc. invested approximately $6.46 million in Zimmer Biomet Holdings, acquiring 57,096 shares during the 1st quarter.
• Zimmer Biomet's earnings exceeded analysts' expectations, reporting $2.07 EPS against a forecast of $1.98, alongside quarterly revenue of $2.08 billion.
• Analysts have mixed ratings on Zimmer Biomet, with an average target price of $111.00, indicating a mix of Buy, Hold, and Sell recommendations.

Polar Asset Management Partners Inc. bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 57,096 shares of the medical equipment provider's stock, valued at approximately $6,462,000.

Other large investors have also recently bought and sold shares of the company. OneDigital Investment Advisors LLC bought a new stake in Zimmer Biomet in the first quarter valued at about $269,000. Keybank National Association OH boosted its holdings in Zimmer Biomet by 61.2% during the first quarter. Keybank National Association OH now owns 14,315 shares of the medical equipment provider's stock valued at $1,620,000 after purchasing an additional 5,434 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Zimmer Biomet by 26.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 316,308 shares of the medical equipment provider's stock valued at $35,800,000 after purchasing an additional 66,114 shares during the period. Kingswood Wealth Advisors LLC raised its holdings in shares of Zimmer Biomet by 20.0% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 2,605 shares of the medical equipment provider's stock worth $295,000 after buying an additional 435 shares in the last quarter. Finally, QRG Capital Management Inc. boosted its stake in Zimmer Biomet by 13.9% in the 1st quarter. QRG Capital Management Inc. now owns 6,775 shares of the medical equipment provider's stock valued at $767,000 after buying an additional 827 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider directly owned 20,424 shares of the company's stock, valued at $1,940,280. This represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.70% of the company's stock.

Zimmer Biomet Trading Down 0.8%

Shares of ZBH stock traded down $0.87 on Tuesday, reaching $103.84. 1,282,597 shares of the stock were exchanged, compared to its average volume of 1,220,309. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72. The stock has a market cap of $20.57 billion, a PE ratio of 13.20, a P/E/G ratio of 2.06 and a beta of 0.68. The stock has a 50 day moving average price of $98.69 and a 200 day moving average price of $99.58.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same period last year, the company earned $2.01 earnings per share. The company's revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet's payout ratio is 23.36%.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Raymond James Financial boosted their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Evercore ISI reduced their price target on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a research report on Tuesday, July 8th. UBS Group raised their price objective on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a report on Friday, August 8th. Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Finally, Canaccord Genuity Group decreased their price target on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Nine equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $111.00.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.